Lead Product(s): Human Monoclonal Antibody
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CERC-002
Highest Development Status: Phase I Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 29, 2021
CERC-002 is a first-in-class anti-LIGHT monoclonal antibody. LIGHT is homologous to lymphotoxin and exhibits an inducible expression. It competes with the HSV glycoprotein D for binding to the herpesvirus entry mediator, a receptor expressed on T lymphocytes.